Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials
about
Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Optimizing the treatment of be ...... of published randomized trials
@ast
Optimizing the treatment of be ...... of published randomized trials
@en
type
label
Optimizing the treatment of be ...... of published randomized trials
@ast
Optimizing the treatment of be ...... of published randomized trials
@en
prefLabel
Optimizing the treatment of be ...... of published randomized trials
@ast
Optimizing the treatment of be ...... of published randomized trials
@en
P2093
P2860
P356
P1476
Optimizing the treatment of be ...... of published randomized trials
@en
P2093
Aizhai Xiang
Jinsong Lu
Wenjin Yin
Xianzhi Chen
P2860
P304
P356
10.2147/OTT.S138600
P407
P577
2017-06-27T00:00:00Z